On March 13, 2018 Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, reported that on March 20, 2018, the Company will release its financial results for the quarter and year ended December 31, 2017 (Press release, , 13 13, 2018, View Source [SID1234524778]). The Company’s management team will host a conference call to discuss the Company’s financial results and recent corporate developments on Tuesday, March 20, 2018 at 8:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3160515.

United States: +1 786-789-4776

Germany: +49 (0)69 2222 13420

Netherlands: +31 (0) 20 721 9251

Denmark: +45 35 15 80 49

France: +33 (0)1 76 77 22 74

Switzerland: +41 (0)22 567 5729

United Kingdom:+44 (0)330 336 9105

An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.